- Home
- RERE vs SIGA Comparison
RERE vs SIGA Comparison
Compare RERE & SIGA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RERE
- SIGA
- Stock Information
- Founded
- RERE 2011
- SIGA 1995
- Country
- RERE China
- SIGA United States
- Employees
- RERE N/A
- SIGA N/A
- Industry
- RERE Other Specialty Stores
- SIGA Biotechnology: Pharmaceutical Preparations
- Sector
- RERE Consumer Discretionary
- SIGA Health Care
- Exchange
- RERE Nasdaq
- SIGA Nasdaq
- Market Cap
- RERE 527.7M
- SIGA 551.0M
- IPO Year
- RERE 2021
- SIGA 1997
- Fundamental
- Price
- RERE $3.02
- SIGA $6.09
- Analyst Decision
- RERE
- SIGA
- Analyst Count
- RERE 0
- SIGA 0
- Target Price
- RERE N/A
- SIGA N/A
- AVG Volume (30 Days)
- RERE 1.9M
- SIGA 517.5K
- Earning Date
- RERE 11-20-2024
- SIGA 11-07-2024
- Dividend Yield
- RERE N/A
- SIGA 9.92%
- EPS Growth
- RERE N/A
- SIGA N/A
- EPS
- RERE N/A
- SIGA 1.20
- Revenue
- RERE $2,188,701,829.00
- SIGA $173,731,386.00
- Revenue This Year
- RERE $28.08
- SIGA $16.79
- Revenue Next Year
- RERE $25.05
- SIGA $15.08
- P/E Ratio
- RERE N/A
- SIGA $5.10
- Revenue Growth
- RERE 27.16
- SIGA 399.31
- 52 Week Low
- RERE $1.01
- SIGA $4.26
- 52 Week High
- RERE $3.70
- SIGA $12.83
- Technical
- Relative Strength Index (RSI)
- RERE 51.97
- SIGA 38.16
- Support Level
- RERE $2.92
- SIGA $5.94
- Resistance Level
- RERE $3.70
- SIGA $6.43
- Average True Range (ATR)
- RERE 0.23
- SIGA 0.40
- MACD
- RERE -0.04
- SIGA -0.07
- Stochastic Oscillator
- RERE 23.60
- SIGA 9.26
About RERE ATRenew Inc.
ATRenew Inc is a pre-owned consumer electronics transactions and services platform in China. The majority of its revenue is derived from online product sales of phones and other consumer electronics goods through its platform. The Company's principal operations and geographic markets are in the People's Republic of China.
About SIGA SIGA Technologies Inc.
SIGA Technologies Inc is a commercial-stage pharmaceutical company focused on the health security market. The company's main product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by the variola virus. The company derives maximum revenue from United States.